Skip to main content
Clinical Trials/NCT03727282
NCT03727282
Unknown
Not Applicable

Use of Transtoracic Ecocargiogram With Calculation of Left Ventricular Volume Index in the Initial Adjustment of Initial Dose of Dobutamine in Patients With Heart Failure and Cardiogenic Shock

University of Sao Paulo General Hospital0 sites30 target enrollmentJanuary 2, 2019

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Cardiogenic Shock
Sponsor
University of Sao Paulo General Hospital
Enrollment
30
Primary Endpoint
cardiac output
Last Updated
7 years ago

Overview

Brief Summary

Recent studies have suggested that the use of left ventricular ejection volume index calculation may aid in the hemodynamic management of critically ill patients. However, a prospective and randomized comparison in patients with heart failure for inotropic dose adjustment has not been described. The objective of this study was to evaluate the efficacy and safety of ejection volume index versus liberal strategy in adjusting dobutamine dose in patients with heart failure and low cardiac output. Methodology: A unicentric, randomized and prospective study will be performed in a comparative manner. Hospital data (test results, medical outcomes, dobutamine dose, complications) of patients will be analyzed for safety and effectiveness. Expected results: The use of ejection volume index is not inferior to the liberal strategy in the initial adjustment of the dose of dobutamine in patients with heart failure.

Registry
clinicaltrials.gov
Start Date
January 2, 2019
End Date
January 2, 2021
Last Updated
7 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • LVEF ≤ 40% documented on echocardiography
  • BNP\> 500 pg / mL
  • Need for initiation of dobutamine and signs or symptoms of low cardiac output at admission defined by the presence of 2 or more of the following:
  • SBP ≤ 95 mmHg
  • FC\> 100 bpm
  • Peripheral vasoconstriction,
  • Cold extremities,
  • Reference of decrease of urine output,
  • Nausea, vomiting and food intolerance,
  • Presence of organic dysfunction

Exclusion Criteria

  • Pregnancy.
  • Hepatical cirrhosis
  • Atrioventricular block of 2nd or 3rd degree. and. SBP \<80 mmHg or need for vasopressor.
  • Use of definitive pacemaker.
  • Body mass index greater than 40 kg / m
  • Use of oral anticoagulant.
  • Acute coronary syndrome.
  • Indication of use of another inotropic other than dobutamine.
  • Orotracheal intubation.
  • Presence of significant pericardial effusion.

Outcomes

Primary Outcomes

cardiac output

Time Frame: 24 hours

echocardiography echocardiography

systolic and diastolic blood pressure

Time Frame: 24 hours

physical evaluation

bicarbonate levels

Time Frame: 24 hours

serum analysis

systolic volume

Time Frame: 24 hours

echocardiography

central venous oxygen saturation levels

Time Frame: 24 hours

serum analysis

heart rate

Time Frame: 24 hours

physical evaluation

base excess levels

Time Frame: 24 hours

serum analysis

arterial lactate levels

Time Frame: 24 hours

serum analysis

creatinine levels

Time Frame: 24 hours

serum analysis

urinary output

Time Frame: 24 hours

urine analysis

urea levels

Time Frame: 24 hours

serum analysis

BNP levels

Time Frame: 24 hours

plasma analysis

troponin levels

Time Frame: 24 hours

serum analysis

Secondary Outcomes

  • worsening of renal function(24 hours)
  • occurrence of sustained ventricular arrhythmia(24 hours)
  • lowering of consciousness level(24 hours)
  • failure of dobutamine weaning up(7 days)
  • need for orotracheal intubation(24 hours)
  • cardiorespiratory arrest(24 hours)
  • need for vasopressor or other inotropic association(24 hours)
  • need for mechanical circulatory assistance(24 hours)
  • death(24 hours)
  • hospitalization time(30 days)

Similar Trials